A Deep Dive Into the CMC, Technology and Financial Aspects of Successful Development of an Orally Delivered GLP-1

This discussion follows on from the first in our series “Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond” and seeks to focus on the drug delivery challenge.

Industry experts will talk through the bioavailability challenge, and offer perspectives on how pharma have successfully addressed this through molecule design and optimization of drug product performance through iterative clinical assessment, before describing how the initial GLP1 therapeutics have stimulated other drug developers to expand into analogous mechanisms of action and small molecule therapeutics

Reasons to listen:

• Building on the first in our series “Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond”
• Learn about the biopharmaceutic considerations for oral GLP1 peptide therapeutics and how industry has innovated to overcome them
• Hear about the health economic considerations of oral peptide delivery
• Get an overview of other developments outside GLP1 peptides to address the obesity therapeutic area

Unable to attend due to a scheduling conflict?  Register now and we will share the content with you afterwards.

Register now